// App-Quantinova.ai

P744 : Ponatinib for Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) With History of Stem Cell Transplantation (SCT): Efficacy and Safety Results of the PACE Trial

Researchers

Presenter

  • F. E. Nicolini

Principal Investigators

  • D. J. DeAngelo

  • E. Abruzzese

  • M. Talpaz

  • J. E. Cortes

  • J. F. Apperley

  • T. L. Holyoake

  • R. A. Larson

  • S. Lustgarten

  • V. M. Rivera

  • T. Clackson

  • M. G. Conlan

  • F. G. Haluska

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom

  • Comprehensive Cancer Center, University of Michigan, Grass Lake, MI

  • Centre for Haematology, Imperial College London, London,

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • The University of Chicago Medical Center, Chicago, IL

  • S Eugenio Hospital, Tor Vergata University, Rome, Italy,

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Locations

  • United States

  • France

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Ponatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved